The estimated Net Worth of Kay A Schmidt is at least $2.1 millió dollars as of 24 August 2022. Kay Schmidt owns over 1,321 units of Catalent stock worth over $1,036,846 and over the last 5 years Kay sold CTLT stock worth over $1,061,987.
Kay has made over 8 trades of the Catalent stock since 2020, according to the Form 4 filled with the SEC. Most recently Kay sold 1,321 units of CTLT stock worth $136,116 on 24 August 2022.
The largest trade Kay's ever made was selling 2,985 units of Catalent stock on 14 October 2020 worth over $278,053. On average, Kay trades about 537 units every 38 days since 2019. As of 24 August 2022 Kay still owns at least 17,388 units of Catalent stock.
You can see the complete history of Kay Schmidt stock trades at the bottom of the page.
Kay's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius és Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: